ArticleJournal of virological methods2007
Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis.
Article in Journal of virological methods, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Biological Nanoparticles in Vaccine Development.Frontiers in bioengineering and biotechnology · 2022Review
- Review
- Recent advances in porphyrin-based nanocomposites for effective targeted imaging and therapy.Biomaterials · 2020Review
- Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses.Frontiers in plant science · 2019Review
- Protein cage assembly across multiple length scales.Chemical Society reviews · 2018Review
- Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery.Bioengineering & translational medicine · 2017Review
- Virus-based nanoparticles as platform technologies for modern vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Biopolymers · 2016Review
- Virus-Based Nanoparticles as Versatile Nanomachines.Annual review of virology · 2015Review
- Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.Vaccines · 2015Review
- Applications of plant viruses in bionanotechnology.Current topics in microbiology and immunology · 2014Review
- Review
- Virus-like particles: the new frontier of vaccines for animal viral infections.Veterinary immunology and immunopathology · 2012Review
- Guiding plant virus particles to integrin-displaying cells.Nanoscale · 2012Article
- Article
- The use of plants for the production of therapeutic human peptides.Plant cell reports · 2012Review
- Article
- Viral vectors for production of recombinant proteins in plants.Journal of cellular physiology · 2008Review
- Purification of Bionanoparticles.Chemical engineering & technology · 2008Article
- Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Chimeric cowpea mosaic virus (CPMV) particles displaying foreign peptide antigens on the particle surface are suitable for development of peptide-based vaccines. However, commonly used PEG precipitation-based purification methods are not sufficient for production of high quality vaccine candidates because they do not allow for separation of chimeric particles from cleaved contaminating species. Moreover, the purified particles remain infectious to plants. To advance the CPMV technology further, it is necessary to develop efficient and scalable purification strategies and preferably eliminate the infectivity of chimeric viruses. CPMV was engineered to display a 25 amino acid peptide derived from the Bacillus anthracis protective antigen on the surface loop of the large coat protein subunit. The engineered virus was propagated in cowpea plants and assembled into chimeric virus particles displaying 60 copies of the peptide on the surface. An effective inactivation method was developed to produce non-infectious chimeric CPMV virus-like particles (VLPs). Uncleaved VLPs were separated from the contaminating cleaved forms by anion exchange chromatography. The yield of purified chimeric VLPs was 0.3 g kg(-1) of leaf tissue. The results demonstrate the ability to generate multi-gram quantities of non-infectious, chimeric CPMV VLPs in plants for use in the development of peptide-based vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.